Meeting
2020 ASCO Virtual Scientific Program
Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
Authors
Michael C. Lowe
Department of Surgery, Emory University, Atlanta, GA
Michael C. Lowe , Brian Olson , Anthony Martinez , Jacklyn Hammons , Keith A. Delman , Melinda Lynne Yushak , Melanie Allor , Christine A. Reilly , Crystal L. Mallow , Elizabeth E. Evans , Terrence Lee Fisher , Gregory B. Lesinski , Ragini Reiney Kudchadkar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT03769155
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10061)
DOI
10.1200/JCO.2020.38.15_suppl.10061
Abstract #
10061
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.
First Author: Michael C. Lowe
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris
Poster
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Richard F. Riedel
Poster
2022 ASCO Annual Meeting
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.
First Author: Thomas Lillie